Free practice quiz
BCACP Prep Course (BCACP): free quiz
10 questions from the program. See your score right away, then unlock the explanation of every answer.
- Question 1 of 10
A 58-year-old adult with type 2 diabetes takes metformin 1000 mg by mouth twice daily and empagliflozin 25 mg by mouth once daily. A1c is 8.6%, BMI 34 kg/m2, eGFR 82 mL/min/1.73 m2, and there is no history of pancreatitis or medullary thyroid carcinoma. As the ambulatory care pharmacist, which medication recommendation is most appropriate to improve glycemic control and support weight loss?
Why A is correct
Semaglutide, a GLP-1 receptor agonist, improves glucose-dependent insulin secretion, slows gastric emptying, and promotes weight loss. In a patient already on metformin and an SGLT2 inhibitor with obesity, it is guideline-concordant and has low hypoglycemia risk. Starting at 0.25 mg weekly reduces gastrointestinal intolerance before titration.
Pharmacist Action: NOTICE persistent A1c elevation plus obesity; SAY weekly injection and GI titration counseling; MONITOR A1c and weight in about 3 months, plus nausea; HOLD/CLARIFY/ESCALATE if prior pancreatitis or severe GI intolerance emerges.Why B is incorrect
Sitagliptin is tempting because it is oral and low risk for hypoglycemia. However, DPP-4 inhibitors are less potent for A1c lowering and are weight neutral, making them less useful when weight loss is desired. Guidelines generally favor GLP-1 receptor agonists over DPP-4 inhibitors in this setting.
Pharmacist Action: NOTICE oral-option preference may bias selection; SAY sitagliptin is usually less effective for weight goals; MONITOR if used, renal function and A1c; HOLD/CLARIFY/ESCALATE if patient expects meaningful weight loss from it.Why C is incorrect
Glyburide is tempting for stronger A1c lowering and low cost. The eliminating fact is its higher hypoglycemia risk and weight gain; glyburide is specifically less favored than other sulfonylureas because of prolonged hypoglycemia. That makes it a poor ambulatory choice here.
Pharmacist Action: NOTICE hypoglycemia and weight-gain risk; SAY low cost does not outweigh safety concerns; MONITOR glucose logs closely if a sulfonylurea is ever used; HOLD/CLARIFY/ESCALATE if recurrent lows occur.Why D is incorrect
Pioglitazone is tempting because it can lower A1c effectively. The single key fact eliminating it is weight gain and edema risk, which work against this patient’s obesity goals and can worsen heart failure risk. It is not the preferred add-on when weight loss is a priority.
Pharmacist Action: NOTICE edema and weight concerns; SAY thiazolidinediones may cause fluid retention; MONITOR weight and edema if prescribed; HOLD/CLARIFY/ESCALATE with dyspnea or heart failure history. - Question 2 of 10
A 58-year-old with diabetes takes empagliflozin 25 mg by mouth daily and metformin XR 1000 mg by mouth twice daily. At a routine call, the patient reports abdominal pain, nausea, rapid breathing, and poor oral intake for 2 days while continuing empagliflozin. What is the best pharmacist recommendation?
Correct Answer
SGLT2 inhibitors can precipitate euglycemic or hyperglycemic ketoacidosis, particularly with poor intake and acute illness. Abdominal pain, nausea, and rapid breathing are concerning and require urgent evaluation; sick-day guidance includes holding the SGLT2 inhibitor pending assessment. The pharmacist should escalate promptly.
Pharmacist Action: NOTICE SGLT2 use plus illness symptoms and tachypnea; SAY urgent evaluation is needed and the SGLT2 inhibitor should be held until assessed; MONITOR hydration, ketone history if available, and symptom progression; ESCALATE same day.
Why the Other Options Are Incorrect
D: Tempting because diabetes may be uncontrolled, but metformin escalation does not address suspected ketoacidosis. A: Tempting as additive therapy, but continuation during acute illness may worsen risk. C: Tempting as a dose-adjustment trap, but any suspected ketoacidosis requires more than a dose reduction.
Pharmacist Action: NOTICE sick-day medication holds for specific agents; SAY this is a safety issue rather than routine A1C optimization; MONITOR renal function and ketone assessment after care; ESCALATE persistent vomiting, dyspnea, or confusion.
- Question 3 of 10
A 50-year-old adult with generalized anxiety disorder takes duloxetine 60 mg by mouth daily and reports bothersome nausea after a recent increase from 30 mg daily 5 days ago. Blood pressure is normal, and there are no alarming symptoms. As the ambulatory care pharmacist, which recommendation is most appropriate?
Correct answer: Step back to the prior tolerated dose
Duloxetine commonly causes dose-related nausea early in therapy or after titration. Returning to the previously tolerated 30 mg dose and retitrating more slowly is a reasonable ambulatory strategy when symptoms are nonurgent. This uses a dose-response principle rather than abandoning the drug immediately.
Pharmacist Action: NOTICE timing of nausea right after dose increase; SAY this often improves with slower titration; MONITOR symptom resolution and anxiety control over 1 to 2 weeks; HOLD/CLARIFY/ESCALATE if persistent vomiting, dehydration, or serotonin-toxicity features occur.Why the other options are incorrect
D: Tempting only if one focuses on efficacy. It is eliminated because nausea is more likely dose related and would likely worsen. C: Tempting because switching can reduce adverse effects. It is eliminated because the new venlafaxine dose is too aggressive and abrupt switching is unnecessary here. A: Tempting not at all clinically; it is eliminated because linezolid is unrelated and introduces a serotonergic interaction risk.
Pharmacist Action: NOTICE dose-related adverse effects before declaring treatment failure; SAY slow titration can preserve adherence; MONITOR tolerability and mood symptoms; HOLD/CLARIFY/ESCALATE if suicidality or severe adverse effects are reported. - Question 4 of 10
A 68-year-old patient with heart failure takes carvedilol 25 mg by mouth twice daily. During an ambulatory vaccination review, the pharmacist identifies risk factors for severe pneumococcal disease. Which condition most strongly increases invasive pneumococcal disease risk?
Why D is correct
Asplenia markedly increases risk of invasive disease from encapsulated organisms such as Streptococcus pneumoniae because splenic clearance and antibody-mediated opsonization are impaired. This is a major vaccine-targeted risk condition.
NOTICE: asplenia as a high-risk immunization indication. SAY: recommend age- and risk-appropriate pneumococcal vaccination. MONITOR: vaccine completion and documentation in the outpatient record. HOLD/CLARIFY/ESCALATE: escalate any febrile illness evaluation concern due to rapid sepsis risk.
Why the others are incorrect
B: Carvedilol is a medication review distractor but does not increase pneumococcal susceptibility. C and A: These are not established invasive pneumococcal risk factors. Review Pneumococcal Risk Conditions — focus on asplenia and immunocompromising states.
- Question 5 of 10
A 48-year-old adult takes omeprazole 20 mg by mouth daily and naproxen 500 mg by mouth twice daily as needed for osteoarthritis. During an annual visit, the ambulatory care pharmacist reviews alcohol use case finding. Which screening approach is recommended in adults, including pregnant persons, in primary care settings when they can be provided brief counseling interventions?
Why C is correct
USPSTF recommends screening adults, including pregnant persons, for unhealthy alcohol use in primary care settings and providing brief behavioral counseling interventions when indicated. The medication context here highlights potential GI risk with alcohol plus NSAID use, but screening is broader than medication exposure alone.
NOTICE: primary care setting and counseling capacity. SAY: use a validated alcohol screen and offer brief counseling if positive. MONITOR: alcohol intake and medication-related GI risks. HOLD/CLARIFY/ESCALATE: urgent escalation if withdrawal risk or severe use disorder is suspected.
Why A is incorrect
Waiting for abnormal liver tests is tempting, but screening aims to identify unhealthy use before organ injury becomes evident.
NOTICE: biochemical abnormalities are not required to screen. SAY: normalize routine screening. MONITOR: AST/ALT separately if clinically indicated. HOLD/CLARIFY/ESCALATE: escalate concerning withdrawal symptoms.
Why D is incorrect
Naproxen plus omeprazole is a medication-related distractor; although alcohol may worsen GI risk, screening should not be limited to this subgroup.
NOTICE: medication interactions can strengthen counseling but do not define screening eligibility. SAY: screen broadly in adults. MONITOR: GI bleeding risk and NSAID use. HOLD/CLARIFY/ESCALATE: urgent evaluation for melena or hematemesis.
Why B is incorrect
Brief counseling interventions do improve outcomes, so avoiding screening is inconsistent with evidence.
NOTICE: screening has value when action follows. SAY: integrate counseling into routine care. MONITOR: readiness to change and follow-up. HOLD/CLARIFY/ESCALATE: refer for specialty treatment when needed.
- Question 6 of 10
A 61-year-old adult with venous thromboembolism takes rivaroxaban 20 mg by mouth each evening with food. Estimated creatinine clearance has declined to 24 mL/min, and there is no active bleeding. As the ambulatory care pharmacist, which recommendation is most appropriate?
Why D is correct
Rivaroxaban has substantial renal elimination, and severe renal impairment increases exposure. For venous thromboembolism treatment or secondary prevention, use becomes problematic at creatinine clearance below labeled thresholds. The pharmacist should recommend reassessing the anticoagulant plan rather than making an unsupported dose reduction. Food improves absorption, not renal clearance.
Pharmacist Action: NOTICE severe renal impairment with a renally influenced DOAC; SAY the current regimen needs reassessment; MONITOR renal function trend and bleeding; HOLD/CLARIFY/ESCALATE if acute kidney injury or bleeding occurs.
Why the other options are incorrect
C: Tempting because taking with food is important, but that does not fix accumulation. A: Tempting as a dose-adjustment trap, yet 10 mg daily is not an evidence-based substitute for this renal situation. B: Tempting as added antithrombotic intensity, but it increases bleeding risk without addressing inappropriate renal use.
Pharmacist Action: NOTICE unsupported dose reductions with DOACs; SAY avoid inventing off-label renal doses; MONITOR for signs of recurrent thrombosis if therapy changes; HOLD/CLARIFY/ESCALATE when kidney function crosses labeled boundaries.
- Question 7 of 10
A 65-year-old patient with nonvalvular atrial fibrillation has been stable on warfarin 3 mg by mouth every evening with therapeutic INRs. The clinic receives a new pharmacogenomic report showing VKORC1 -1639 A/A. As the ambulatory care pharmacist, what is the best interpretation of this result?
Why A is correct
VKORC1 -1639 A/A is associated with increased sensitivity to warfarin and lower dose requirements. In a patient already therapeutic on 3 mg daily, this genotype supports why a relatively low maintenance dose is sufficient. Genotype informs dose expectation but does not replace INR-based management. NOTICE: New VKORC1 sensitivity result in a patient stable on warfarin 3 mg nightly. SAY: Explain that the genotype aligns with lower dose needs but ongoing INR monitoring remains standard. MONITOR: INR, bleeding, diet consistency, and interacting medications. HOLD/CLARIFY/ESCALATE: Escalate for supratherapeutic INR, bleeding, or major medication changes.
Why the other options are incorrect
C: Tempting if A/A is mistaken for resistance, but it predicts sensitivity, not resistance. D: Tempting because the patient is stable, yet INR remains necessary because diet, illness, and interactions still alter response. B: Tempting if direct oral anticoagulants are confused with warfarin pharmacogenomics, but VKORC1 is directly relevant to warfarin.
- Question 8 of 10
A 52-year-old adult with chronic hepatitis B takes tenofovir alafenamide 25 mg by mouth daily. As the ambulatory care pharmacist, the patient reports missing doses because housing instability makes it hard to store medications safely and maintain a routine. Viral suppression has been inconsistent. Which pharmacist recommendation is best?
Why B is correct
Housing instability is a structural adherence barrier. In ambulatory care, practical medication storage strategies, synchronized access, and interprofessional support can improve persistence without compromising antiviral exposure. Linking social needs to medication planning is central to access-oriented care.
NOTICE: unstable housing undermining adherence. SAY: “We can adjust the refill process and connect support services to protect your treatment.” MONITOR: refill gaps and HBV treatment continuity. HOLD/CLARIFY/ESCALATE: escalate if treatment interruptions are ongoing or hepatic concerns arise.
Why the other options are incorrect
A: Tempting because it stretches supply. It is eliminated because subtherapeutic dosing risks virologic failure. D: Tempting because it acknowledges social instability. It is eliminated because planned interruptions can worsen disease control. C: Tempting because changing agents may seem useful. It is eliminated because twice-daily dosing generally worsens adherence and is not an access solution.
NOTICE: social determinant directly affecting medication persistence. SAY: use nonjudgmental language and problem-solve logistics. MONITOR: adherence and refill completion monthly. HOLD/CLARIFY/ESCALATE: collaborate with prescriber and support team when interruptions occur.
- Question 9 of 10
A patient taking omeprazole 20 mg by mouth every morning says, “I keep using it longer than planned because I get symptoms when I stop.” Which pharmacist response best demonstrates a neutral, curious approach?
Why D is correct
A neutral, curious question encourages the patient to describe rebound symptoms, fears, and prior attempts without feeling judged. This is consistent with motivational interviewing and helps the pharmacist tailor education and deprescribing support for omeprazole.
Pharmacist Action: NOTICE difficulty discontinuing therapy and concern about symptoms. SAY “Tell me what you notice when you stop.” MONITOR symptom recurrence, timing, and use of rescue therapy. HOLD/CLARIFY/ESCALATE if alarm symptoms or GI bleeding concerns need medical evaluation.
Why the other options are incorrect
A labels the patient experience in a way that may increase defensiveness. B gives advice before understanding the patient’s experience. C is tempting because regimen changes are sometimes discussed, but switching PPIs does not inherently solve the issue. Review Motivational Interviewing Core Skills — focus on curiosity over labeling.
- Question 10 of 10
A pharmacist in a family medicine clinic assesses a 63-year-old adult with gastroesophageal reflux disease taking omeprazole 20 mg by mouth every morning. The patient also takes clopidogrel 75 mg by mouth daily after coronary stent placement 2 months ago. Reflux symptoms persist despite adherence. Which acid-suppressive recommendation is most appropriate?
Why D is correct
Pantoprazole is a proton pump inhibitor with less clinically important CYP2C19 inhibition than omeprazole or esomeprazole, making it a preferred PPI choice when clopidogrel is needed. It maintains acid suppression without the same interaction concern.
NOTICE the clopidogrel-PPI interaction risk. SAY changing to a different PPI can preserve antiplatelet effect while treating reflux. MONITOR reflux symptoms and adherence after the switch, typically within 2 to 8 weeks. HOLD/CLARIFY/ESCALATE if chest pain is concerning for cardiac causes rather than reflux.
Why the others are incorrect
B: Higher-dose omeprazole may improve symptoms, but it worsens the same interaction concern. A: Cimetidine can reduce acid, yet it is less effective than PPIs and has many drug interaction liabilities. C: Esomeprazole shares the same major CYP2C19 inhibition issue as omeprazole.
NOTICE when a symptom-control option conflicts with cardiovascular therapy. SAY not all PPIs are equally suitable with clopidogrel. MONITOR for symptom relief and any new medication changes. HOLD/CLARIFY/ESCALATE if alarm GI symptoms such as dysphagia or weight loss appear.
See why each answer is right or wrong
Enter your email to unlock the explanation of every question, free.


